Let there be light

February 2006
Gut;Feb2006, Vol. 55 Issue 2, p275
Academic Journal
The presents the abstract of the article "Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international partially blinded, randomized phase III trial," by B. Overholt, C. J. Lightdale and K. K. Wang.


Related Articles

  • Photodynamic therapy's role likely to grow. Zabel, Karen // Dermatology Times;May97, Vol. 18 Issue 5, p1 

    Provides information on the significance of photodynamic therapy (PDT) in the treatment of nonmelanoma cutaneous malignancies. Photosensitizing agents being studied; Why do patients choose PDT; Potential uses of PDT; Major disadvantage of PDT.

  • ERRATUM.  // Journal of Dental Research;Nov2007, Vol. 86 Issue 11, p1126 

    A correction to the article "Photodynamic Therapy in Dentisty," in the August, 2007 issue of the publication is presented.

  • Photodynamic Therapy: A Review. McCaughan Jr, J.S. // Drugs & Aging;1999, Vol. 15 Issue 1, p49 

    Photodynamic therapy (PDT) of malignant tumours is a new technique for treating cancers. After intravenous injection, a photosensitiser is selectively retained by the tumour cells so after time there is more sensitiser in the tumour than in the normal adjacent tissue. The photosensitiser must be...

  • Lamp blasts away skin cancer. Higgins, Amy; Koucky, Sherri; Waltz, Vicky // Machine Design;9/13/2001, Vol. 73 Issue 17, p28 

    Focuses on the Paterson photodynamic therapy that treats cancer with nonlaser light. Principle behind the process; Advantages.

  • Photodynamic therapy offers promising results. Groves, Nancy // Dermatology Times;Nov2000, Vol. 21 Issue 11, p36 

    Reports on the results of clinical trials of photodynamic therapy with temoporfin for the treatment of primary, secondary, and advanced head and neck cancer. Response rates; Reduction in tumor size; Other benefits to patients; Treatment of other cancers.

  • CMS Recognizes PDT's Worth for Occult Lesions.  // Review of Ophthalmology;Nov2001, Vol. 8 Issue 11, p5 

    Analyzes the effectiveness of photodynamic therapy with verteporfin in treating patients with occult choroidal neovascular lesions in the United States. Proposal for the expansion of treatment coverage; Consideration on the coverage for ocular photodynamic therapy with verteporfin; Improvements...

  • Kinetic studies on the mechanism of haematoporphyrin derivative photobleaching. Chekulayeva, Lyudmila; Shevchuk, Igor; Chekulayev, Vladimir; Jallaid, Raissa // Proceedings of the Estonian Academy of Sciences, Chemistry;Mar2002, Vol. 51 Issue 1, p49 

    Haematoporphyrin derivative (HPD), a sensitizer used in photodynamic therapy (PDT) of tumours, is progressively destroyed (photobleached) during illumination. However, the mechanism of the sensitizer photobleaching remains unclear, although its degradation presents both potential problems and...

  • Seeing the light. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the photodynamic cancer drug Photofrin. Food and Drug Administration (FDA) approval; Mechanism of action; Development by QLT Therapeutics; Applications; Marketing plans; Expectations.

  • Side glance: Photodynamic therapy.  // JNCI: Journal of the National Cancer Institute;4/19/95, Vol. 87 Issue 8, p562 

    Describes the process and applications of photodynamic therapy. Application on tumor cells; Activation of drug-induced oxygen-dependent chemical reactions; Conduct of clinical trials for the treatment of cancers.


Read the Article


Sign out of this library

Other Topics